Front Line Genomics brought together thought leaders from around the world to discuss New Approaches to the Old Hunt for NASH Therapies, available to watch on-demand. The conversation was moderated by Donna Cryer, the President and CEO of the Global Liver Institute. The panel discussed why there has been limited progress in therapies for nonalcoholic […]
NASH is present in nine to 18 million people in America alone. Yet no single drug has yet been approved for its treatment. To discuss why therapies are proving so elusive, and where efforts will be made in the future, FLG has gathered some of the most influential names in the field to discuss the problem in our latest webinar: New Approaches to the Old Hunt for NASH Therapies, held at 4pm on 11 July 2019.